Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-AKT1 Polyclonal Antibody 2 is a Rabbit antibody targeting AKT1. Anti-AKT1 Polyclonal Antibody 2 can be used in WB.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μL | $221 | 7-10 days | |
100 μL | $373 | 7-10 days | |
200 μL | $527 | 7-10 days |
Description | Antibody Type: Rabbit Polyclonal Application: WB Reactivity: Human,Mouse,Rat (predicted:Chicken,Dog,Pig,Cow,Rabbit,Sheep) |
Ig Type | IgG |
Reactivity | Human,Mouse,Rat (predicted:Chicken,Dog,Pig,Cow,Rabbit,Sheep) |
Verified Activity | 1. Tissue/cell: A549 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum) at 37°C for 20 min; Antibody incubation with (AKT1) polyclonal Antibody, Unconjugated (TMAB-00088) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue) was used to stain the cell nucleus. 2. Blank control: A549. Primary Antibody (green line): Rabbit Anti-AKT1 antibody (TMAB-00088) Dilution: 2 μg/10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG. Secondary Antibody: Goat anti-rabbit IgG-FITC Dilution: 1 μg/test. Protocol The cells were incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. 3. 25 μg total protein per Lane of various lysates probed with AKT1 polyclonal antibody, unconjugated (TMAB-00088) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at RT for 60 min. |
Application | WB |
Recommended Dose | WB: 1:500-2000 |
Antibody Type | Polyclonal |
Host Species | Rabbit |
Subcellular Localization | Cytoplasm. Nucleus. Cell membrane. Note=Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus. |
Construction | Hybridoma Polyclonal Antibody |
Purification | Protein A purified |
Appearance | Liquid |
Formulation | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Research Background | This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020] |
Immunogen | KLH conjugated synthetic peptide: human PKB |
Antigen Species | Human |
Gene ID | 207 |
Uniprot ID | |
Biology Area | Metabolism,AKT,Nuclear,Apoptosis,PKB / AKT |
Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.